

IN THE UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

---

IN RE SUBOXONE (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE) ANTITRUST LITIGATION	:	MDL NO. 2445 13-MD-2445
THIS DOCUMENT RELATES TO:,	:	
<i>Wisconsin, et al. v. Indivior Inc. et al.</i>	:	
Case No. 16-cv-5073	:	
STATE OF WISCONSIN	:	
By Attorney General Brad D. Schimel, et al.	:	
Plaintiffs,	:	CIV. A. NO. 16-5073
v.	:	
INDIVIOR INC. f/k/a RECKITT BENCKISER PHARMACEUTICALS, INC., et al.	:	
Defendants.	:	
	:	

---

**ORDER**

AND NOW, this 19<sup>th</sup> day of February, 2021, upon consideration of (1) Defendant Indivior's Phase II Motion to Exclude Certain of the Opinions of Russell Lamb, Ernst Berndt, Rena Conti, Eric Emch, and the Pricing-Related Opinions of Laurence Westreich, and Yvonne Tso (MDL No. 13-2445, Doc. No. 661) and Plaintiffs' Response (MDL No. 13-2445, Doc. No. 671); (2) Defendant Aquestive Therapeutics, Inc.'s Motion to Exclude Dr. Ernst Berndt (MDL No. 13-2445, Doc. No. 660; Civ. A. No. 16-5073, Doc. No. 415) and the State Plaintiffs' Response (MDL No. 13-2445, Doc. No. 674; Civ. A. No. 16-5073, Doc. No. 424); and (3) the Direct Purchaser Plaintiffs' Motion for Leave to File an *Amicus* Brief in Opposition to Defendant Aquestive's Motion to Exclude Dr. Berndt (Civ. A. No. 16-5073, Doc. No. 425) and Aquestive's Response (Civ. A. No. 16-5073, Doc. No. 428), it is hereby **ORDERED** that:

1. Indivior's Phase II Motion to Exclude (MDL No. 13-2445, Doc. No. 661) is **DENIED** as set forth in the Court's accompanying Memorandum Opinion.
2. Aquestive's Motion to Exclude (MDL No. 13-2445, Doc. No. 660; Civ. A. No. 16-5073, Doc. No. 415) is **DENIED** as set forth in the Court's accompanying Memorandum Opinion.
3. The Direct Purchaser Plaintiffs' Motion for Leave to File an *Amicus* Brief (Civ. A. No. 16-5073, Doc. No. 425) is **DENIED AS MOOT**.

**BY THE COURT:**

/s/ Mitchell S. Goldberg  
MITCHELL S. GOLDBERG, J.